Key clinical point: A greater proportion of patients with rheumatoid arthritis (RA) initially treated with oral baricitinib maintained lower levels of radiographic progression over 5 years than those initially treated with conventional synthetic disease-modifying antirheumatic drugs or placebo.

Major finding: At 5 years, no radiographic progression was achieved by a greater proportion of DMARD-naive patients with initial treatment with 4 mg baricitinib (59.0%) and initial treatment with 4 mg baricitinib + methotrexate (66.2%) vs. those with initial methotrexate treatment (40.7%). Similarly, a greater proportion of patients with inadequate response to methotrexate with initial baricitinib treatment (54.8%) or adalimumab treatment (55.0%) achieved no progression vs. those with initial placebo treatment (50.3%).

Study details: Findings are from a long-term extension RA-BEYOND trial, which included 2,125 patients with active adult-onset RA who completed any 1 of RA-BEGIN, RA-BEAM, or RA-BUILD phase 3 trials.

Disclosures: Eli Lilly and Company supported this study. The authors declared receiving grant/research support and consulting/speaker’s fees from various sources including Eli Lilly and Company. Three authors reported being current or former employees and shareholders of Eli Lilly.

Source: van der Heijde D et al. J Rheumatol. 2021 Sep 15. doi: 10.3899/jrheum.210346.

Key clinical point: A greater proportion of patients with rheumatoid arthritis (RA) initially treated with oral baricitinib maintained lower levels of radiographic progression over 5 years than those initially treated with conventional synthetic disease-modifying antirheumatic drugs or placebo.

Major finding: At 5 years, no radiographic progression was achieved by a greater proportion of DMARD-naive patients with initial treatment with 4 mg baricitinib (59.0%) and initial treatment with 4 mg baricitinib + methotrexate (66.2%) vs. those with initial methotrexate treatment (40.7%). Similarly, a greater proportion of patients with inadequate response to methotrexate with initial baricitinib treatment (54.8%) or adalimumab treatment (55.0%) achieved no progression vs. those with initial placebo treatment (50.3%).

Study details: Findings are from a long-term extension RA-BEYOND trial, which included 2,125 patients with active adult-onset RA who completed any 1 of RA-BEGIN, RA-BEAM, or RA-BUILD phase 3 trials.

Disclosures: Eli Lilly and Company supported this study. The authors declared receiving grant/research support and consulting/speaker’s fees from various sources including Eli Lilly and Company. Three authors reported being current or former employees and shareholders of Eli Lilly.

Source: van der Heijde D et al. J Rheumatol. 2021 Sep 15. doi: 10.3899/jrheum.210346.

Key clinical point: A greater proportion of patients with rheumatoid arthritis (RA) initially treated with oral baricitinib maintained lower levels of radiographic progression over 5 years than those initially treated with conventional synthetic disease-modifying antirheumatic drugs or placebo.

Major finding: At 5 years, no radiographic progression was achieved by a greater proportion of DMARD-naive patients with initial treatment with 4 mg baricitinib (59.0%) and initial treatment with 4 mg baricitinib + methotrexate (66.2%) vs. those with initial methotrexate treatment (40.7%). Similarly, a greater proportion of patients with inadequate response to methotrexate with initial baricitinib treatment (54.8%) or adalimumab treatment (55.0%) achieved no progression vs. those with initial placebo treatment (50.3%).

Study details: Findings are from a long-term extension RA-BEYOND trial, which included 2,125 patients with active adult-onset RA who completed any 1 of RA-BEGIN, RA-BEAM, or RA-BUILD phase 3 trials.

Disclosures: Eli Lilly and Company supported this study. The authors declared receiving grant/research support and consulting/speaker’s fees from various sources including Eli Lilly and Company. Three authors reported being current or former employees and shareholders of Eli Lilly.

Source: van der Heijde D et al. J Rheumatol. 2021 Sep 15. doi: 10.3899/jrheum.210346.

Key clinical point: Premenopausal women with rheumatoid arthritis (RA) had a significantly higher risk for diastolic dysfunction, and early screening may help prevent future cardiovascular events.

Major finding: Patients with RA had a significantly higher incidence of diastolic dysfunction (odds ratio [OR] 2.18; P = .020), with the risk being higher in women aged between 30 and 49 years vs. control participants of the same age (OR 3.54; 95% CI 1.27-9.85).

Study details: This study involved 61 premenopausal women with RA without any history of hypertension matched with 107 control participants.

Disclosures: No funding or financial conflict of interests was reported.

Source: Kim GH et al. Arthritis Res Ther. 2021 (Sep 24);23:247. doi: 10.1186/s13075-021-02629-1.

Key clinical point: Premenopausal women with rheumatoid arthritis (RA) had a significantly higher risk for diastolic dysfunction, and early screening may help prevent future cardiovascular events.

Major finding: Patients with RA had a significantly higher incidence of diastolic dysfunction (odds ratio [OR] 2.18; P = .020), with the risk being higher in women aged between 30 and 49 years vs. control participants of the same age (OR 3.54; 95% CI 1.27-9.85).

Study details: This study involved 61 premenopausal women with RA without any history of hypertension matched with 107 control participants.

Disclosures: No funding or financial conflict of interests was reported.

Source: Kim GH et al. Arthritis Res Ther. 2021 (Sep 24);23:247. doi: 10.1186/s13075-021-02629-1.

Key clinical point: Premenopausal women with rheumatoid arthritis (RA) had a significantly higher risk for diastolic dysfunction, and early screening may help prevent future cardiovascular events.

Major finding: Patients with RA had a significantly higher incidence of diastolic dysfunction (odds ratio [OR] 2.18; P = .020), with the risk being higher in women aged between 30 and 49 years vs. control participants of the same age (OR 3.54; 95% CI 1.27-9.85).

Study details: This study involved 61 premenopausal women with RA without any history of hypertension matched with 107 control participants.

Disclosures: No funding or financial conflict of interests was reported.

Source: Kim GH et al. Arthritis Res Ther. 2021 (Sep 24);23:247. doi: 10.1186/s13075-021-02629-1.

Key clinical point: Sarilumab monotherapy was as effective as its combination with methotrexate in patients with rheumatoid arthritis (RA). Hence, it could be a suitable alternative in patients with contraindications or intolerance to methotrexate.

Major finding: At 24 weeks, sarilumab vs. sarilumab + methotrexate groups had comparable least square mean change from baseline with overlapping confidence intervals for Clinical Disease Activity Index (−28.79 vs. −26.21), 28-joint Disease Activity using C-reactive protein (−2.95 vs. −2.81), and pain visual analog scale (−33.62 vs. −31.66).

Study details: This was a post hoc analysis of 184 patients with RA who received sarilumab in the MONARCH trial and 399 patients with RA with inadequate response to methotrexate, who received a combination of sarilumab and methotrexate in the MOBILITY trial.

Disclosures: Sanofi provided funding for this study. The authors including the lead author reported receiving grants/research support, consultancy, speaker’s fees, and consultancy fees or honoraria from various sources. A Praestgaard and HV Hoogstraten reported being employees of Sanofi and may hold stock or stock options in the company.

Source: Burmester GR et al. Rheumatology (Oxford). 2021 Sep 11. doi: 10.1093/rheumatology/keab676.

Key clinical point: Sarilumab monotherapy was as effective as its combination with methotrexate in patients with rheumatoid arthritis (RA). Hence, it could be a suitable alternative in patients with contraindications or intolerance to methotrexate.

Major finding: At 24 weeks, sarilumab vs. sarilumab + methotrexate groups had comparable least square mean change from baseline with overlapping confidence intervals for Clinical Disease Activity Index (−28.79 vs. −26.21), 28-joint Disease Activity using C-reactive protein (−2.95 vs. −2.81), and pain visual analog scale (−33.62 vs. −31.66).

Study details: This was a post hoc analysis of 184 patients with RA who received sarilumab in the MONARCH trial and 399 patients with RA with inadequate response to methotrexate, who received a combination of sarilumab and methotrexate in the MOBILITY trial.

Disclosures: Sanofi provided funding for this study. The authors including the lead author reported receiving grants/research support, consultancy, speaker’s fees, and consultancy fees or honoraria from various sources. A Praestgaard and HV Hoogstraten reported being employees of Sanofi and may hold stock or stock options in the company.

Source: Burmester GR et al. Rheumatology (Oxford). 2021 Sep 11. doi: 10.1093/rheumatology/keab676.

Key clinical point: Sarilumab monotherapy was as effective as its combination with methotrexate in patients with rheumatoid arthritis (RA). Hence, it could be a suitable alternative in patients with contraindications or intolerance to methotrexate.

Major finding: At 24 weeks, sarilumab vs. sarilumab + methotrexate groups had comparable least square mean change from baseline with overlapping confidence intervals for Clinical Disease Activity Index (−28.79 vs. −26.21), 28-joint Disease Activity using C-reactive protein (−2.95 vs. −2.81), and pain visual analog scale (−33.62 vs. −31.66).

Study details: This was a post hoc analysis of 184 patients with RA who received sarilumab in the MONARCH trial and 399 patients with RA with inadequate response to methotrexate, who received a combination of sarilumab and methotrexate in the MOBILITY trial.

Disclosures: Sanofi provided funding for this study. The authors including the lead author reported receiving grants/research support, consultancy, speaker’s fees, and consultancy fees or honoraria from various sources. A Praestgaard and HV Hoogstraten reported being employees of Sanofi and may hold stock or stock options in the company.

Source: Burmester GR et al. Rheumatology (Oxford). 2021 Sep 11. doi: 10.1093/rheumatology/keab676.

Key clinical point: Exposure to biologic disease-modifying antirheumatic drugs (bDMARD) did not seem to be associated with an elevated risk for recurrent or new cancer in patients with rheumatoid arthritis (RA) and a history of cancer.

Major finding: The risk for recurrent or new cancer was not significantly higher in patients with RA receiving bDMARDs (relative risk [RR], 1.09; P = .31), tumor necrosis factor inhibitors (RR 1.11; P = .45), or rituximab (RR 0.79; P = .49) vs. those not receiving bDMARDs.

Study details: This was a meta-analysis of 12 observational studies involving patients with RA who had a history of cancer and received bDMARDs.

Disclosures: No specific funding was received for this study. The authors declared receiving honoraria or grants from various sources.

Source: Wetzman A et al. Arthritis Care Res (Hoboken). 2021 Sep 21. doi: 10.1002/acr.24784.

Key clinical point: Exposure to biologic disease-modifying antirheumatic drugs (bDMARD) did not seem to be associated with an elevated risk for recurrent or new cancer in patients with rheumatoid arthritis (RA) and a history of cancer.

Major finding: The risk for recurrent or new cancer was not significantly higher in patients with RA receiving bDMARDs (relative risk [RR], 1.09; P = .31), tumor necrosis factor inhibitors (RR 1.11; P = .45), or rituximab (RR 0.79; P = .49) vs. those not receiving bDMARDs.

Study details: This was a meta-analysis of 12 observational studies involving patients with RA who had a history of cancer and received bDMARDs.

Disclosures: No specific funding was received for this study. The authors declared receiving honoraria or grants from various sources.

Source: Wetzman A et al. Arthritis Care Res (Hoboken). 2021 Sep 21. doi: 10.1002/acr.24784.

Key clinical point: Exposure to biologic disease-modifying antirheumatic drugs (bDMARD) did not seem to be associated with an elevated risk for recurrent or new cancer in patients with rheumatoid arthritis (RA) and a history of cancer.

Major finding: The risk for recurrent or new cancer was not significantly higher in patients with RA receiving bDMARDs (relative risk [RR], 1.09; P = .31), tumor necrosis factor inhibitors (RR 1.11; P = .45), or rituximab (RR 0.79; P = .49) vs. those not receiving bDMARDs.

Study details: This was a meta-analysis of 12 observational studies involving patients with RA who had a history of cancer and received bDMARDs.

Disclosures: No specific funding was received for this study. The authors declared receiving honoraria or grants from various sources.

Source: Wetzman A et al. Arthritis Care Res (Hoboken). 2021 Sep 21. doi: 10.1002/acr.24784.

Key clinical point: Discontinuation of denosumab after 1 year of treatment showed a return to baseline lumbar spine (LS) and total hip (TH) bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids.

Major finding: By 12 months after discontinuation, TH BMD reduced to levels similar to or slightly above placebo in patients receiving 60 mg (P = .210) and 180 mg denosumab (P = .706). Similar reversal of gains was observed for LS BMD with the least-square percent mean change from baseline in placebo, 60 mg, and 180 mg denosumab, being 2.30% (95% CI −0.35%-4.94%), 1.31% (95% CI −1.17%-3.79%), and 0.12% (95% CI −2.45%-2.68%), respectively.

Study details: This was a post hoc analysis of a phase 2 study including 82 patients with RA receiving glucocorticoids, randomly assigned to placebo, 60 mg, or 180 mg denosumab every 6 months for 12 months.

Disclosures: The study was sponsored by Amgen Inc. Some of the authors declared ties with various sources including Amgen. MT McDermott, RK Stad, L Chen, and S Huang declared being employees of Amgen.

Source: Saag KG et al. Arthritis Rheumatol. 2021 Sep 17. doi: 10.1002/art.41981.

Key clinical point: Discontinuation of denosumab after 1 year of treatment showed a return to baseline lumbar spine (LS) and total hip (TH) bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids.

Major finding: By 12 months after discontinuation, TH BMD reduced to levels similar to or slightly above placebo in patients receiving 60 mg (P = .210) and 180 mg denosumab (P = .706). Similar reversal of gains was observed for LS BMD with the least-square percent mean change from baseline in placebo, 60 mg, and 180 mg denosumab, being 2.30% (95% CI −0.35%-4.94%), 1.31% (95% CI −1.17%-3.79%), and 0.12% (95% CI −2.45%-2.68%), respectively.

Study details: This was a post hoc analysis of a phase 2 study including 82 patients with RA receiving glucocorticoids, randomly assigned to placebo, 60 mg, or 180 mg denosumab every 6 months for 12 months.

Disclosures: The study was sponsored by Amgen Inc. Some of the authors declared ties with various sources including Amgen. MT McDermott, RK Stad, L Chen, and S Huang declared being employees of Amgen.

Source: Saag KG et al. Arthritis Rheumatol. 2021 Sep 17. doi: 10.1002/art.41981.

Key clinical point: Discontinuation of denosumab after 1 year of treatment showed a return to baseline lumbar spine (LS) and total hip (TH) bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids.

Major finding: By 12 months after discontinuation, TH BMD reduced to levels similar to or slightly above placebo in patients receiving 60 mg (P = .210) and 180 mg denosumab (P = .706). Similar reversal of gains was observed for LS BMD with the least-square percent mean change from baseline in placebo, 60 mg, and 180 mg denosumab, being 2.30% (95% CI −0.35%-4.94%), 1.31% (95% CI −1.17%-3.79%), and 0.12% (95% CI −2.45%-2.68%), respectively.

Study details: This was a post hoc analysis of a phase 2 study including 82 patients with RA receiving glucocorticoids, randomly assigned to placebo, 60 mg, or 180 mg denosumab every 6 months for 12 months.

Disclosures: The study was sponsored by Amgen Inc. Some of the authors declared ties with various sources including Amgen. MT McDermott, RK Stad, L Chen, and S Huang declared being employees of Amgen.

Source: Saag KG et al. Arthritis Rheumatol. 2021 Sep 17. doi: 10.1002/art.41981.

Key clinical point: Despite higher initial disease activity, patients with rheumatoid arthritis (RA) who received biologic disease-modifying antirheumatic drugs (bDMARDs) vs. conventional synthetic DMARDs (csDMARDs) had a lower incidence of total knee replacement (TKR) and total hip replacement (THR).

Major finding: The incidence of TKR (incidence rate ratio [IRR] 0.72; 95% CI 0.62-0.83) and THR (IRR 0.77; 95% CI 0.64-0.93) was significantly lower in patients receiving biologics vs. those who received csDMARDs, with TKR (adjusted hazard ratio [aHR] 0.55; 95% CI 0.38-0.81) and THR (aHR 0.63; 95% CI 0.40-0.98) risk being lowest in patients with regular bDMARD use.

Study details: This was a nationwide retrospective study involving 48,165 patients with RA. Patients receiving biologics without undergoing TKR (n = 5,979) or THR (n = 6,245) formed the biologic cohort matched with control cohorts comprising 11,958 and 12,490 patients receiving csDMARDs, respectively.

Disclosures: No specific funding or conflict of interests was reported.

Source: Chang YS et al. Rheumatology (Oxford). 2021 Sep 17. doi: 10.1093/rheumatology/keab671.

Key clinical point: Despite higher initial disease activity, patients with rheumatoid arthritis (RA) who received biologic disease-modifying antirheumatic drugs (bDMARDs) vs. conventional synthetic DMARDs (csDMARDs) had a lower incidence of total knee replacement (TKR) and total hip replacement (THR).

Major finding: The incidence of TKR (incidence rate ratio [IRR] 0.72; 95% CI 0.62-0.83) and THR (IRR 0.77; 95% CI 0.64-0.93) was significantly lower in patients receiving biologics vs. those who received csDMARDs, with TKR (adjusted hazard ratio [aHR] 0.55; 95% CI 0.38-0.81) and THR (aHR 0.63; 95% CI 0.40-0.98) risk being lowest in patients with regular bDMARD use.

Study details: This was a nationwide retrospective study involving 48,165 patients with RA. Patients receiving biologics without undergoing TKR (n = 5,979) or THR (n = 6,245) formed the biologic cohort matched with control cohorts comprising 11,958 and 12,490 patients receiving csDMARDs, respectively.

Disclosures: No specific funding or conflict of interests was reported.

Source: Chang YS et al. Rheumatology (Oxford). 2021 Sep 17. doi: 10.1093/rheumatology/keab671.

Key clinical point: Despite higher initial disease activity, patients with rheumatoid arthritis (RA) who received biologic disease-modifying antirheumatic drugs (bDMARDs) vs. conventional synthetic DMARDs (csDMARDs) had a lower incidence of total knee replacement (TKR) and total hip replacement (THR).

Major finding: The incidence of TKR (incidence rate ratio [IRR] 0.72; 95% CI 0.62-0.83) and THR (IRR 0.77; 95% CI 0.64-0.93) was significantly lower in patients receiving biologics vs. those who received csDMARDs, with TKR (adjusted hazard ratio [aHR] 0.55; 95% CI 0.38-0.81) and THR (aHR 0.63; 95% CI 0.40-0.98) risk being lowest in patients with regular bDMARD use.

Study details: This was a nationwide retrospective study involving 48,165 patients with RA. Patients receiving biologics without undergoing TKR (n = 5,979) or THR (n = 6,245) formed the biologic cohort matched with control cohorts comprising 11,958 and 12,490 patients receiving csDMARDs, respectively.

Disclosures: No specific funding or conflict of interests was reported.

Source: Chang YS et al. Rheumatology (Oxford). 2021 Sep 17. doi: 10.1093/rheumatology/keab671.

Key clinical point: After adjustment for hyperlipidemia, the risk of developing rheumatoid arthritis (RA) was not higher among statin users than nonusers.

Major finding: After adjusting for hyperlipidemia, the risk of developing RA was not higher among former users of statins (adjusted odds ratio [aOR] 1.03; 95% CI 0.96-1.10) and was slightly lower among current users (aOR 0.87; 95% CI 0.81-0.93) than nonusers.

Study details: This was a nationwide case-control study of 16,363 patients with RA and a similar number of matched control participants.

Disclosures: The National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute on Aging funded this work. None of the authors declared any conflict of interest.

Source: Peterson MN et al. Arthritis Res Ther. 2021 (Sep 18):23:244. doi: 10.1186/s13075-021-02617-5.

Key clinical point: After adjustment for hyperlipidemia, the risk of developing rheumatoid arthritis (RA) was not higher among statin users than nonusers.

Major finding: After adjusting for hyperlipidemia, the risk of developing RA was not higher among former users of statins (adjusted odds ratio [aOR] 1.03; 95% CI 0.96-1.10) and was slightly lower among current users (aOR 0.87; 95% CI 0.81-0.93) than nonusers.

Study details: This was a nationwide case-control study of 16,363 patients with RA and a similar number of matched control participants.

Disclosures: The National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute on Aging funded this work. None of the authors declared any conflict of interest.

Source: Peterson MN et al. Arthritis Res Ther. 2021 (Sep 18):23:244. doi: 10.1186/s13075-021-02617-5.

Key clinical point: After adjustment for hyperlipidemia, the risk of developing rheumatoid arthritis (RA) was not higher among statin users than nonusers.

Major finding: After adjusting for hyperlipidemia, the risk of developing RA was not higher among former users of statins (adjusted odds ratio [aOR] 1.03; 95% CI 0.96-1.10) and was slightly lower among current users (aOR 0.87; 95% CI 0.81-0.93) than nonusers.

Study details: This was a nationwide case-control study of 16,363 patients with RA and a similar number of matched control participants.

Disclosures: The National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute on Aging funded this work. None of the authors declared any conflict of interest.

Source: Peterson MN et al. Arthritis Res Ther. 2021 (Sep 18):23:244. doi: 10.1186/s13075-021-02617-5.

Key clinical point: A switch from adalimumab (ADL), sourced from the European Union (ADL-EU), to ADL biosimilar PF-06410293 (ADL-PF) had no effect on long-term treatment efficacy and safety in patients with active rheumatoid arthritis (RA).

Major finding: The American College of Rheumatology 20 response rate was sustained and similar in patients maintained on ADL-PF and those who switched from ADL-EU to ADL-PF at weeks 26 and 52 (52 weeks: 88.4%, 88.2%, and 87.6%, respectively; 78 weeks: 83.4%, 85.8%, and 84.3%, respectively). From weeks 52-78, the incidence of treatment-related adverse events was 42.6%, 37.0%, and 50.8% for the biosimilar, week 26 switch, and week 52 switch groups, respectively.

Study details: Findings are from an analysis of 597 patients with RA and an inadequate response to methotrexate who continued ADL-PF treatment throughout 78 weeks or switched from ADL-EU to ADL-PF at week 26 or 52 in the phase 3 REFLECTIONS B538-02 trial.

Disclosures: The study was sponsored by Pfizer. Five authors reported being employees and shareholders of Pfizer, and two reported receiving grants/support and consulting fees from several sources.

Source: Fleischmann RM. Arthritis Res Ther. 2021(Sep 25);23:248. doi: 10.1186/s13075-021-02626-4.

Key clinical point: A switch from adalimumab (ADL), sourced from the European Union (ADL-EU), to ADL biosimilar PF-06410293 (ADL-PF) had no effect on long-term treatment efficacy and safety in patients with active rheumatoid arthritis (RA).

Major finding: The American College of Rheumatology 20 response rate was sustained and similar in patients maintained on ADL-PF and those who switched from ADL-EU to ADL-PF at weeks 26 and 52 (52 weeks: 88.4%, 88.2%, and 87.6%, respectively; 78 weeks: 83.4%, 85.8%, and 84.3%, respectively). From weeks 52-78, the incidence of treatment-related adverse events was 42.6%, 37.0%, and 50.8% for the biosimilar, week 26 switch, and week 52 switch groups, respectively.

Study details: Findings are from an analysis of 597 patients with RA and an inadequate response to methotrexate who continued ADL-PF treatment throughout 78 weeks or switched from ADL-EU to ADL-PF at week 26 or 52 in the phase 3 REFLECTIONS B538-02 trial.

Disclosures: The study was sponsored by Pfizer. Five authors reported being employees and shareholders of Pfizer, and two reported receiving grants/support and consulting fees from several sources.

Source: Fleischmann RM. Arthritis Res Ther. 2021(Sep 25);23:248. doi: 10.1186/s13075-021-02626-4.

Key clinical point: A switch from adalimumab (ADL), sourced from the European Union (ADL-EU), to ADL biosimilar PF-06410293 (ADL-PF) had no effect on long-term treatment efficacy and safety in patients with active rheumatoid arthritis (RA).

Major finding: The American College of Rheumatology 20 response rate was sustained and similar in patients maintained on ADL-PF and those who switched from ADL-EU to ADL-PF at weeks 26 and 52 (52 weeks: 88.4%, 88.2%, and 87.6%, respectively; 78 weeks: 83.4%, 85.8%, and 84.3%, respectively). From weeks 52-78, the incidence of treatment-related adverse events was 42.6%, 37.0%, and 50.8% for the biosimilar, week 26 switch, and week 52 switch groups, respectively.

Study details: Findings are from an analysis of 597 patients with RA and an inadequate response to methotrexate who continued ADL-PF treatment throughout 78 weeks or switched from ADL-EU to ADL-PF at week 26 or 52 in the phase 3 REFLECTIONS B538-02 trial.

Disclosures: The study was sponsored by Pfizer. Five authors reported being employees and shareholders of Pfizer, and two reported receiving grants/support and consulting fees from several sources.

Source: Fleischmann RM. Arthritis Res Ther. 2021(Sep 25);23:248. doi: 10.1186/s13075-021-02626-4.

Key clinical point: The prevalence of low lean mass and sarcopenic obesity was significantly higher in patients with rheumatoid arthritis (RA) than the general reference population.

Major finding: Patients with RA compared to reference populations from NHANES and HealthABC had a greater prevalence of low lean mass (14.2% vs. 10.0% and 7.0%, respectively; all P < .001) and sarcopenic obesity (12.6% vs. 4.5% and 4.0%, respectively; all P < .001), with both associated with worse Health Assessment Questionnaire scores, suggesting worse disability (P < .001).

Study details: The findings came from the analysis of 113, 190, and 141 patients with RA from the University of Pennsylvania, Events in RA study, and University of San Francisco cohorts, respectively, compared with reference populations from NHANES and HealthABC.

Disclosures: This work was supported by a VA Clinical Science Research and Development Award, the National Institutes of Health, the University of Pennsylvania Clinical and Translational Research Center, among others. JF Bater declared receiving consulting fees from Bristol Myers Squibb, Gilead, and Pfizer.

Source: Baker JF et al. Rheumatology (Oxford). 2021 Sep 24. doi: 10.1093/rheumatology/keab710.

Key clinical point: The prevalence of low lean mass and sarcopenic obesity was significantly higher in patients with rheumatoid arthritis (RA) than the general reference population.

Major finding: Patients with RA compared to reference populations from NHANES and HealthABC had a greater prevalence of low lean mass (14.2% vs. 10.0% and 7.0%, respectively; all P < .001) and sarcopenic obesity (12.6% vs. 4.5% and 4.0%, respectively; all P < .001), with both associated with worse Health Assessment Questionnaire scores, suggesting worse disability (P < .001).

Study details: The findings came from the analysis of 113, 190, and 141 patients with RA from the University of Pennsylvania, Events in RA study, and University of San Francisco cohorts, respectively, compared with reference populations from NHANES and HealthABC.

Disclosures: This work was supported by a VA Clinical Science Research and Development Award, the National Institutes of Health, the University of Pennsylvania Clinical and Translational Research Center, among others. JF Bater declared receiving consulting fees from Bristol Myers Squibb, Gilead, and Pfizer.

Source: Baker JF et al. Rheumatology (Oxford). 2021 Sep 24. doi: 10.1093/rheumatology/keab710.

Key clinical point: The prevalence of low lean mass and sarcopenic obesity was significantly higher in patients with rheumatoid arthritis (RA) than the general reference population.

Major finding: Patients with RA compared to reference populations from NHANES and HealthABC had a greater prevalence of low lean mass (14.2% vs. 10.0% and 7.0%, respectively; all P < .001) and sarcopenic obesity (12.6% vs. 4.5% and 4.0%, respectively; all P < .001), with both associated with worse Health Assessment Questionnaire scores, suggesting worse disability (P < .001).

Study details: The findings came from the analysis of 113, 190, and 141 patients with RA from the University of Pennsylvania, Events in RA study, and University of San Francisco cohorts, respectively, compared with reference populations from NHANES and HealthABC.

Disclosures: This work was supported by a VA Clinical Science Research and Development Award, the National Institutes of Health, the University of Pennsylvania Clinical and Translational Research Center, among others. JF Bater declared receiving consulting fees from Bristol Myers Squibb, Gilead, and Pfizer.

Source: Baker JF et al. Rheumatology (Oxford). 2021 Sep 24. doi: 10.1093/rheumatology/keab710.

Motor imagery (MI) is a useful tool in the management of multiple sclerosis (MS), with the potential to improve balance, walking, and even cognitive function and mental health. It’s a technique that many think of as the realm of professional athletes, who use it to help mentally prepare for physical activity. But the underlying mechanism has broad applicability, even in patients with MS who have disability.

The method recruits and employs motor-related areas within the brain, which suggests that it has functional equivalence to carrying out the rehearsed movement. The mental chronometry is also similar between imagined and executed actions, said Barbara Seebacher, PhD, who discussed MI during a presentation at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

MI involves mentally rehearsing movements, and so requires working memory. The patient must also have the fundamental ability to carry out the action, so it isn’t much use having nonambulatory patients imagine themselves walking. “The mental representations need to be available,” said Dr. Seebacher, a researcher at Medical University of Innsbruck in Austria.

During MI, individuals may imagine themselves from a first- or third-person view. The experience may be visual, as in picturing oneself moving, or kinesthetic, as in imagining the feeling of movement. There can be implicit components, such as imagining a projection of the speed and distance of an approaching car, and explicit, such as imagining the personal movement of walking across the street.

The use of MI in MS rehabilitation is a relatively new development, with no reports before 2010. One early, uncontrolled study found improvements in fatigue and quality of life when MI was combined with physical practice in 20 patients. Another study published in 2012 found that MS patients had worse MI accuracy and temporal organization than that of healthy controls, and that MI accuracy was associated with cognitive impairment.

A study in 2012 used visual and rhythmic cues combined with MI, and compared results when those cues were present or absent during MI. The cues produced much better results. Dr. Seebacher’s group has used rhythmic, auditory-cued MI of walking in people with MS. Approaches included music cueing, music and verbal cueing, metronome and verbal cueing, and no cue MI. “We found significant effects after all of these approaches, but the greatest effects were shown after music and verbally-cued MI practice,” said Dr. Seebacher.

MI ability appears to be impaired by longer MS disease duration, more severe disability, depression and anxiety, and cognitive fatigue. “All of this contributes to timing deficits in performing mental movements and to deficits in the spatial organization of imagined movements,” said Dr. Seebacher.

In contrast, studies have shown that MI training improves dynamic balance, walking, perceived walking ability, balance, confidence, cognition, fatigue, anxiety and depression, quality of life, and health-related quality of life.

Rehabilitation specialists can help patients achieve success with MI by letting them select their preferred perspective, first or third person, at least during initial sessions. Patients can also be given the choice to use a more dexterous, more often-used body part, at least in initial MI sessions. External rhythmic, audio, or visual cuing can be offered.

Dr. Seebacher has developed an initial framework for helping patients to improve their MI ability. This includes assessing rhythmicity of single imagined movements to help ensure that MI and movements are functionally equivalent. Another step is to incorporate movements that are meaningful to the patients, to help ensure that they are emotionally engaged with the exercise. Research conducted primarily in stroke patients has shown that embedding physical practice into MI, or adding physical movement to MI, can enhance sensory feedback.

Motor learning principles from neurorehabilitation also apply to MI, such as beginning with simple tasks and progressing to more complex tasks, as well as use of blocked practice before turning to random practice. “All this should help our patients to perform MI more easily and to gain a greater benefit,” said Dr. Seebacher.

The potential of MI piqued the interest of comoderator Hanneke Hulst, PhD, assistant professor of neurology at Amsterdam University Medical Center, during the Q&A session. “It’s actually very intriguing and interesting,” she said, and then asked Dr. Seebacher how difficult MI is to implement in a rehabilitation program, especially for someone who isn’t a rehabilitation specialist.

Dr. Seebacher responded that it can be difficult, especially because patients and therapists usually aren’t familiar with MI. “Whenever I explain MI to patients, I compare it with athletes, because everybody knows that athletes use mental training, together with their physical training. And this is something patients can identify themselves with,” said Dr. Seebacher. It’s also vital that the patient has preserved cognitive function, and is open to a new therapeutic approach. “If somebody just wants to act the same way that they did all the time, it may not be useful for these patients,” said Dr. Seebacher.

MI is also useful for patients who have difficulty with physical training, for example following relapses, or for those who are at greater risk of falling.

Dr. Seebacher has no relevant financial disclosures. Dr. Hulst has consulted with or served on the scientific advisory boards of Biogen, Celgene, Genzyme, Merck, and Roche.

Motor imagery (MI) is a useful tool in the management of multiple sclerosis (MS), with the potential to improve balance, walking, and even cognitive function and mental health. It’s a technique that many think of as the realm of professional athletes, who use it to help mentally prepare for physical activity. But the underlying mechanism has broad applicability, even in patients with MS who have disability.

The method recruits and employs motor-related areas within the brain, which suggests that it has functional equivalence to carrying out the rehearsed movement. The mental chronometry is also similar between imagined and executed actions, said Barbara Seebacher, PhD, who discussed MI during a presentation at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

MI involves mentally rehearsing movements, and so requires working memory. The patient must also have the fundamental ability to carry out the action, so it isn’t much use having nonambulatory patients imagine themselves walking. “The mental representations need to be available,” said Dr. Seebacher, a researcher at Medical University of Innsbruck in Austria.

During MI, individuals may imagine themselves from a first- or third-person view. The experience may be visual, as in picturing oneself moving, or kinesthetic, as in imagining the feeling of movement. There can be implicit components, such as imagining a projection of the speed and distance of an approaching car, and explicit, such as imagining the personal movement of walking across the street.

The use of MI in MS rehabilitation is a relatively new development, with no reports before 2010. One early, uncontrolled study found improvements in fatigue and quality of life when MI was combined with physical practice in 20 patients. Another study published in 2012 found that MS patients had worse MI accuracy and temporal organization than that of healthy controls, and that MI accuracy was associated with cognitive impairment.

A study in 2012 used visual and rhythmic cues combined with MI, and compared results when those cues were present or absent during MI. The cues produced much better results. Dr. Seebacher’s group has used rhythmic, auditory-cued MI of walking in people with MS. Approaches included music cueing, music and verbal cueing, metronome and verbal cueing, and no cue MI. “We found significant effects after all of these approaches, but the greatest effects were shown after music and verbally-cued MI practice,” said Dr. Seebacher.

MI ability appears to be impaired by longer MS disease duration, more severe disability, depression and anxiety, and cognitive fatigue. “All of this contributes to timing deficits in performing mental movements and to deficits in the spatial organization of imagined movements,” said Dr. Seebacher.

In contrast, studies have shown that MI training improves dynamic balance, walking, perceived walking ability, balance, confidence, cognition, fatigue, anxiety and depression, quality of life, and health-related quality of life.

Rehabilitation specialists can help patients achieve success with MI by letting them select their preferred perspective, first or third person, at least during initial sessions. Patients can also be given the choice to use a more dexterous, more often-used body part, at least in initial MI sessions. External rhythmic, audio, or visual cuing can be offered.

Dr. Seebacher has developed an initial framework for helping patients to improve their MI ability. This includes assessing rhythmicity of single imagined movements to help ensure that MI and movements are functionally equivalent. Another step is to incorporate movements that are meaningful to the patients, to help ensure that they are emotionally engaged with the exercise. Research conducted primarily in stroke patients has shown that embedding physical practice into MI, or adding physical movement to MI, can enhance sensory feedback.

Motor learning principles from neurorehabilitation also apply to MI, such as beginning with simple tasks and progressing to more complex tasks, as well as use of blocked practice before turning to random practice. “All this should help our patients to perform MI more easily and to gain a greater benefit,” said Dr. Seebacher.

The potential of MI piqued the interest of comoderator Hanneke Hulst, PhD, assistant professor of neurology at Amsterdam University Medical Center, during the Q&A session. “It’s actually very intriguing and interesting,” she said, and then asked Dr. Seebacher how difficult MI is to implement in a rehabilitation program, especially for someone who isn’t a rehabilitation specialist.

Dr. Seebacher responded that it can be difficult, especially because patients and therapists usually aren’t familiar with MI. “Whenever I explain MI to patients, I compare it with athletes, because everybody knows that athletes use mental training, together with their physical training. And this is something patients can identify themselves with,” said Dr. Seebacher. It’s also vital that the patient has preserved cognitive function, and is open to a new therapeutic approach. “If somebody just wants to act the same way that they did all the time, it may not be useful for these patients,” said Dr. Seebacher.

MI is also useful for patients who have difficulty with physical training, for example following relapses, or for those who are at greater risk of falling.

Dr. Seebacher has no relevant financial disclosures. Dr. Hulst has consulted with or served on the scientific advisory boards of Biogen, Celgene, Genzyme, Merck, and Roche.

Motor imagery (MI) is a useful tool in the management of multiple sclerosis (MS), with the potential to improve balance, walking, and even cognitive function and mental health. It’s a technique that many think of as the realm of professional athletes, who use it to help mentally prepare for physical activity. But the underlying mechanism has broad applicability, even in patients with MS who have disability.

The method recruits and employs motor-related areas within the brain, which suggests that it has functional equivalence to carrying out the rehearsed movement. The mental chronometry is also similar between imagined and executed actions, said Barbara Seebacher, PhD, who discussed MI during a presentation at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

MI involves mentally rehearsing movements, and so requires working memory. The patient must also have the fundamental ability to carry out the action, so it isn’t much use having nonambulatory patients imagine themselves walking. “The mental representations need to be available,” said Dr. Seebacher, a researcher at Medical University of Innsbruck in Austria.

During MI, individuals may imagine themselves from a first- or third-person view. The experience may be visual, as in picturing oneself moving, or kinesthetic, as in imagining the feeling of movement. There can be implicit components, such as imagining a projection of the speed and distance of an approaching car, and explicit, such as imagining the personal movement of walking across the street.

The use of MI in MS rehabilitation is a relatively new development, with no reports before 2010. One early, uncontrolled study found improvements in fatigue and quality of life when MI was combined with physical practice in 20 patients. Another study published in 2012 found that MS patients had worse MI accuracy and temporal organization than that of healthy controls, and that MI accuracy was associated with cognitive impairment.

A study in 2012 used visual and rhythmic cues combined with MI, and compared results when those cues were present or absent during MI. The cues produced much better results. Dr. Seebacher’s group has used rhythmic, auditory-cued MI of walking in people with MS. Approaches included music cueing, music and verbal cueing, metronome and verbal cueing, and no cue MI. “We found significant effects after all of these approaches, but the greatest effects were shown after music and verbally-cued MI practice,” said Dr. Seebacher.

MI ability appears to be impaired by longer MS disease duration, more severe disability, depression and anxiety, and cognitive fatigue. “All of this contributes to timing deficits in performing mental movements and to deficits in the spatial organization of imagined movements,” said Dr. Seebacher.

In contrast, studies have shown that MI training improves dynamic balance, walking, perceived walking ability, balance, confidence, cognition, fatigue, anxiety and depression, quality of life, and health-related quality of life.

Rehabilitation specialists can help patients achieve success with MI by letting them select their preferred perspective, first or third person, at least during initial sessions. Patients can also be given the choice to use a more dexterous, more often-used body part, at least in initial MI sessions. External rhythmic, audio, or visual cuing can be offered.

Dr. Seebacher has developed an initial framework for helping patients to improve their MI ability. This includes assessing rhythmicity of single imagined movements to help ensure that MI and movements are functionally equivalent. Another step is to incorporate movements that are meaningful to the patients, to help ensure that they are emotionally engaged with the exercise. Research conducted primarily in stroke patients has shown that embedding physical practice into MI, or adding physical movement to MI, can enhance sensory feedback.

Motor learning principles from neurorehabilitation also apply to MI, such as beginning with simple tasks and progressing to more complex tasks, as well as use of blocked practice before turning to random practice. “All this should help our patients to perform MI more easily and to gain a greater benefit,” said Dr. Seebacher.

The potential of MI piqued the interest of comoderator Hanneke Hulst, PhD, assistant professor of neurology at Amsterdam University Medical Center, during the Q&A session. “It’s actually very intriguing and interesting,” she said, and then asked Dr. Seebacher how difficult MI is to implement in a rehabilitation program, especially for someone who isn’t a rehabilitation specialist.

Dr. Seebacher responded that it can be difficult, especially because patients and therapists usually aren’t familiar with MI. “Whenever I explain MI to patients, I compare it with athletes, because everybody knows that athletes use mental training, together with their physical training. And this is something patients can identify themselves with,” said Dr. Seebacher. It’s also vital that the patient has preserved cognitive function, and is open to a new therapeutic approach. “If somebody just wants to act the same way that they did all the time, it may not be useful for these patients,” said Dr. Seebacher.

MI is also useful for patients who have difficulty with physical training, for example following relapses, or for those who are at greater risk of falling.

Dr. Seebacher has no relevant financial disclosures. Dr. Hulst has consulted with or served on the scientific advisory boards of Biogen, Celgene, Genzyme, Merck, and Roche.